Data availability
The data supporting this study’s findings are available from the corresponding author upon reasonable request.
References
Paschka P, Döhner K (2013) Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Hematol Am Soc Hematol Educ Program 2013:209–219
Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C et al (2004) Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741–3750
Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027–1036
Martin-Broto J, Moura DS (2020) New drugs in gastrointestinal stromal tumors. Curr Opin Oncol 32:314–320
Guido M, Susan G, Kristina L, Weiqiang Z, Donna B et al (2020) Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Advance 4:696–705
Samantha B, Laura CM (2021) Avapritinib in the treatment of systemic mastocytosis: an update. Curr Hematol Malig Rep 16:464–472
Prithviraj B, Srdan V (2021) Avapritinib for systemic mastocytosis. Expert Rev Hematol 14:687–696
Funding
This study was funded by the grant from the National Key R&D Program of China (2019YFA0111000), the National Natural Science Foundation of China (81900130, 81970136, 81970142, 82000132, 8217011130, 8210010924), the Natural Science Foundation of the Jiangsu Higher Education Institution of China (18KJA320005), the Natural Science Foundation of Jiangsu Province (BK20190180), priority academic program development of Jiangsu Higher Education Institution, the Innovation Capability Development Project of Jiangsu Province (BM215004), the Translational Research Grant of NCRCH (2020WSB03, 2020WSB11, 2020WSB13), and the Open Project of Jiangsu Biobank of Clinical Resources (SBK202003001, SBK202003003).
Author information
Authors and Affiliations
Contributions
Jia Yin collected and analyzed data and wrote the first draft of the manuscript; Feng Zhu and Zhi-Bo Zhang collected the data and edited the paper; Qian Wang, Xue-Feng He, Qian Wu, and Jing-Ren Zhang provided patient care; Ai-Ning Sun, De-Pei Wu, Xiao-Fei Yang, and Su-Ning Chen designed research, analyzed data, and wrote the manuscript. The submission has been read and approved for submission by all authors.
Corresponding authors
Ethics declarations
Ethics approval
This case study has completely complied with the human research regulations and ethical requirements issued by the Ethics Committee of the First Affiliated Hospital of Soochow University.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Jia Yin, Feng Zhu, and Zhi-Bo Zhang are co-first authors.
Rights and permissions
About this article
Cite this article
Yin, J., Zhu, F., Zhang, ZB. et al. Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation. Ann Hematol 101, 2347–2350 (2022). https://doi.org/10.1007/s00277-022-04897-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-022-04897-6